<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en" dir="ltr">
  <head>
    <meta http-equiv="Content-Type" content="text/html; charset=UTF-8" />
    		<meta name="keywords" content="Alefacept,Alefacept.png,Immunosuppressants,Immunosuppressants,2006,ATC code L04,Abatacept,Abscess,Adalimumab,Adverse drug reaction,Afelimomab" />
		<link rel="shortcut icon" href="/favicon.ico" />
		<link rel="search" type="application/opensearchdescription+xml" href="/w/opensearch_desc.php" title="Wikipedia (English)" />
		<link rel="copyright" href="../../../COPYING.html" />
    <title>Alefacept - Wikipedia, the free encyclopedia</title>
    <style type="text/css">/*<![CDATA[*/ @import "../../../skins/htmldump/main.css"; /*]]>*/</style>
    <link rel="stylesheet" type="text/css" media="print" href="../../../skins/common/commonPrint.css" />
    <!--[if lt IE 5.5000]><style type="text/css">@import "../../../skins/monobook/IE50Fixes.css";</style><![endif]-->
    <!--[if IE 5.5000]><style type="text/css">@import "../../../skins/monobook/IE55Fixes.css";</style><![endif]-->
    <!--[if IE 6]><style type="text/css">@import "../../../skins/monobook/IE60Fixes.css";</style><![endif]-->
    <!--[if IE]><script type="text/javascript" src="../../../skins/common/IEFixes.js"></script>
    <meta http-equiv="imagetoolbar" content="no" /><![endif]-->
    <script type="text/javascript" src="../../../skins/common/wikibits.js"></script>
    <script type="text/javascript" src="../../../skins/htmldump/md5.js"></script>
    <script type="text/javascript" src="../../../skins/htmldump/utf8.js"></script>
    <script type="text/javascript" src="../../../skins/htmldump/lookup.js"></script>
    <script type="text/javascript" src="../../../raw/gen.js"></script>        <style type="text/css">/*<![CDATA[*/
@import "../../../raw/MediaWiki%7ECommon.css";
@import "../../../raw/MediaWiki%7EMonobook.css";
@import "../../../raw/gen.css";
/*]]>*/</style>          </head>
  <body
    class="ns-0">
    <div id="globalWrapper">
      <div id="column-content">
	<div id="content">
	  <a name="top" id="contentTop"></a>
	        <h1 class="firstHeading">Alefacept</h1>
	  <div id="bodyContent">
	    <h3 id="siteSub">From Wikipedia, the free encyclopedia</h3>
	    <div id="contentSub"></div>
	    	    	    <!-- start content -->
	    <table id="drugInfoBox" style="float: right; clear: right; margin: 0 0 0.5em 1em; background: #ffffff;" class="toccolours" border="0" cellpadding="1" align="right" width="280">
<tr>
<td align="center" colspan="2"><a href="../../../u/p/l/Special%7EUpload_3661.html" class="new" title="Image:Alefacept.png">Image:Alefacept.png</a></td>
</tr>
<tr>
<td align="center" colspan="2">
<div style="font-size:medium; line-height:167%;">Alefacept</div>
</td>
</tr>
<tr>
<td colspan="2" bgcolor="#DDDDDD"><b>Systematic (<a href="../../../i/n/t/International_Union_of_Pure_and_Applied_Chemistry_nomenclature_efd4.html" title="International Union of Pure and Applied Chemistry nomenclature">IUPAC</a>) name</b></td>
</tr>
<tr>
<td bgcolor="#EEEEEE" style="text-align: center; vertical-align: top;" colspan="2"><span style="font-size:11px">1-92-LFA-3 (Antigen) (human) fusion protein with immunoglobin G1 (human hinge CH2-CH3γ1-chain) dimer</span></td>
</tr>
<tr>
<td colspan="2" bgcolor="#DDDDDD"><b>Identifiers</b></td>
</tr>
<tr>
<td bgcolor="#DDEEFF" width="90"><a href="../../../c/a/s/CAS_registry_number_4b20.html" title="CAS registry number">CAS number</a></td>
<td bgcolor="#EEEEEE"><span class="reflink plainlinksneverexpand"><a href="http://www.nlm.nih.gov/cgi/mesh/2006/MB_cgi?term=222535-22-0&amp;rn=1" class="external text" title="http://www.nlm.nih.gov/cgi/mesh/2006/MB_cgi?term=222535-22-0&amp;rn=1" rel="nofollow">222535-22-0</a></span></td>
</tr>
<tr>
<td bgcolor="#DDEEFF"><a href="../../../a/n/a/Anatomical_Therapeutic_Chemical_Classification_System_186e.html" title="Anatomical Therapeutic Chemical Classification System">ATC code</a></td>
<td bgcolor="#EEEEEE"><a href="../../../a/t/c/ATC_code_L04_d7fc.html" title="ATC code L04">L04</a><span class="reflink plainlinksneverexpand"><a href="http://www.whocc.no/atcddd/indexdatabase/index.php?query=L04AA15" class="external text" title="http://www.whocc.no/atcddd/indexdatabase/index.php?query=L04AA15" rel="nofollow">AA15</a></span></td>
</tr>
<tr>
<td bgcolor="#DDEEFF"><a href="../../../p/u/b/PubChem_a50b.html" title="PubChem">PubChem</a></td>
<td bgcolor="#EEEEEE">&#160;?</td>
</tr>
<tr>
<td bgcolor="#DDEEFF"><a href="../../../d/r/u/DrugBank_2050.html" title="DrugBank">DrugBank</a></td>
<td bgcolor="#EEEEEE"><span class="reflink plainlinksneverexpand"><a href="http://redpoll.pharmacy.ualberta.ca/drugbank/cgi-bin/getCard.cgi?CARD=BTD00055" class="external text" title="http://redpoll.pharmacy.ualberta.ca/drugbank/cgi-bin/getCard.cgi?CARD=BTD00055" rel="nofollow">BTD00055</a></span></td>
</tr>
<tr>
<td colspan="2" bgcolor="#DDDDDD"><b>Chemical data</b></td>
</tr>
<tr>
<td bgcolor="#DDEEFF"><a href="../../../c/h/e/Chemical_formula.html" title="Chemical formula">Formula</a></td>
<td bgcolor="#EEEEEE"><a href="../../../c/a/r/Carbon.html" title="Carbon"><span style="color: rgb(000,000,000); font-weight: bold;">C</span></a><sub>2306</sub><a href="../../../h/y/d/Hydrogen.html" title="Hydrogen"><span style="color: rgb(77,77,77); font-weight: bold;">H</span></a><sub>3594</sub><a href="../../../n/i/t/Nitrogen.html" title="Nitrogen"><span style="color: rgb(0,0,128); font-weight: bold;">N</span></a><sub>610</sub><a href="../../../o/x/y/Oxygen.html" title="Oxygen"><span style="color: rgb(116,35,35); font-weight: bold;">O</span></a><sub>694</sub><a href="../../../s/u/l/Sulfur.html" title="Sulfur"><span style="color: rgb(114,97,31); font-weight: bold;">S</span></a><sub>26</sub><sup>&#160;</sup></td>
</tr>
<tr>
<td bgcolor="#DDEEFF"><a href="../../../m/o/l/Molecular_mass.html" title="Molecular mass">Mol. mass</a></td>
<td bgcolor="#EEEEEE">51801.1 g/mol</td>
</tr>
<tr>
<td colspan="2" bgcolor="#DDDDDD"><b>Pharmacokinetic data</b></td>
</tr>
<tr>
<td bgcolor="#DDEEFF" style="vertical-align: top;"><a href="../../../b/i/o/Bioavailability.html" title="Bioavailability">Bioavailability</a></td>
<td bgcolor="#EEEEEE">63% (<a href="../../../i/n/t/Intramuscular_injection.html" title="Intramuscular injection">IM</a>)</td>
</tr>
<tr>
<td bgcolor="#DDEEFF" style="vertical-align: top;"><a href="../../../d/r/u/Drug_metabolism.html" title="Drug metabolism">Metabolism</a></td>
<td bgcolor="#EEEEEE">&#160;?</td>
</tr>
<tr>
<td bgcolor="#DDEEFF" style="vertical-align: top;"><a href="../../../b/i/o/Biological_half-life.html" title="Biological half-life">Half life</a></td>
<td bgcolor="#EEEEEE">~270 hours</td>
</tr>
<tr>
<td bgcolor="#DDEEFF" style="vertical-align: top;"><a href="../../../e/x/c/Excretion.html" title="Excretion">Excretion</a></td>
<td bgcolor="#EEEEEE">&#160;?</td>
</tr>
<tr>
<td colspan="2" bgcolor="#DDDDDD"><b>Therapeutic considerations</b></td>
</tr>
<tr>
<td bgcolor="#DDEEFF" style="vertical-align: top;"><a href="../../../p/r/e/Pregnancy_category.html" title="Pregnancy category">Pregnancy cat.</a></td>
<td bgcolor="#EEEEEE">
<p>C<small>(<a href="../../../a/u/s/Australia.html" title="Australia">AU</a>)</small> B<small>(<a href="../../../u/n/i/United_States_09d4.html" title="United States">US</a>)</small></p>
</td>
</tr>
<tr>
<td bgcolor="#DDEEFF" style="vertical-align: top;"><a href="../../../r/e/g/Regulation_of_therapeutic_goods.html" title="Regulation of therapeutic goods">Legal status</a></td>
<td bgcolor="#EEEEEE">
<p><a href="../../../p/r/e/Prescription_drug.html" title="Prescription drug"><span class="Unicode">℞</span><small>-only</small></a><small>(<a href="../../../u/n/i/United_States_09d4.html" title="United States">US</a>)</small></p>
</td>
</tr>
<tr>
<td bgcolor="#DDEEFF" style="vertical-align: top;"><a href="../../../r/o/u/Route_of_administration.html" title="Route of administration">Routes</a></td>
<td bgcolor="#EEEEEE"><a href="../../../i/n/t/Intravenous_therapy.html" title="Intravenous therapy">Intravenous</a>, <a href="../../../i/n/t/Intramuscular_injection.html" title="Intramuscular injection">intramuscular</a></td>
</tr>
</table>
<p><b>Alefacept</b> is a <a href="../../../g/e/n/Genetic_engineering.html" title="Genetic engineering">genetically engineered</a> <a href="../../../i/m/m/Immunosuppressive_drug.html" title="Immunosuppressive drug">immunosuppressive drug</a> sold under the brand name <b>Amevive®</b> in <a href="../../../c/a/n/Canada.html" title="Canada">Canada</a>, the <a href="../../../u/n/i/United_States_09d4.html" title="United States">United States</a>, and <a href="../../../a/u/s/Australia.html" title="Australia">Australia</a>. It is used to control <a href="../../../i/n/f/Inflammation.html" title="Inflammation">inflammation</a> in moderate to severe <a href="../../../p/s/o/Psoriasis.html" title="Psoriasis">psoriasis</a> with <a href="../../../p/l/a/Plaque.html" title="Plaque">plaque</a> formation, where it interferes with <a href="../../../l/y/m/Lymphocyte.html" title="Lymphocyte">lymphocyte</a> activation.<sup id="_ref-0" class="reference"><a href="#_note-0" title="">[1]</a></sup></p>
<table id="toc" class="toc" summary="Contents">
<tr>
<td>
<div id="toctitle">
<h2>Contents</h2>
</div>
<ul>
<li class="toclevel-1"><a href="#Mode_of_Action"><span class="tocnumber">1</span> <span class="toctext">Mode of Action</span></a></li>
<li class="toclevel-1"><a href="#Drawbacks"><span class="tocnumber">2</span> <span class="toctext">Drawbacks</span></a></li>
<li class="toclevel-1"><a href="#Indications"><span class="tocnumber">3</span> <span class="toctext">Indications</span></a></li>
<li class="toclevel-1"><a href="#Contraindications_and_Precautions"><span class="tocnumber">4</span> <span class="toctext">Contraindications and Precautions</span></a></li>
<li class="toclevel-1"><a href="#Pregnancy_and_Lactation"><span class="tocnumber">5</span> <span class="toctext">Pregnancy and Lactation</span></a></li>
<li class="toclevel-1"><a href="#Pediatric_Patients"><span class="tocnumber">6</span> <span class="toctext">Pediatric Patients</span></a></li>
<li class="toclevel-1"><a href="#Side_effects"><span class="tocnumber">7</span> <span class="toctext">Side effects</span></a></li>
<li class="toclevel-1"><a href="#Interactions"><span class="tocnumber">8</span> <span class="toctext">Interactions</span></a></li>
<li class="toclevel-1"><a href="#Necessary_Laboratory_Examinations"><span class="tocnumber">9</span> <span class="toctext">Necessary Laboratory Examinations</span></a></li>
<li class="toclevel-1"><a href="#Dosage_Regimes"><span class="tocnumber">10</span> <span class="toctext">Dosage Regimes</span></a></li>
<li class="toclevel-1"><a href="#Notes"><span class="tocnumber">11</span> <span class="toctext">Notes</span></a></li>
<li class="toclevel-1"><a href="#External_links"><span class="tocnumber">12</span> <span class="toctext">External links</span></a></li>
</ul>
</td>
</tr>
</table>
<script type="text/javascript">
//<![CDATA[
 if (window.showTocToggle) { var tocShowText = "show"; var tocHideText = "hide"; showTocToggle(); } 
//]]>
</script>
<p><a name="Mode_of_Action" id="Mode_of_Action"></a></p>
<h2><span class="editsection">[<a href="../../../a/l/e/Alefacept.html" title="Edit section: Mode of Action">edit</a>]</span> <span class="mw-headline">Mode of Action</span></h2>
<p>The exact mode of action is very complicated, but is has been explored that alefacept inhibits the activation of CD2<sup>+</sup>, <a href="../../../c/d/4/CD4_f7b4.html" title="CD4">CD4</a><sup>+</sup>, and <a href="../../../c/d/8/CD8_b6d0.html" title="CD8">CD8</a><sup>+</sup> <a href="../../../t/_/c/T_cell.html" title="T cell">T cells</a> which in return stimulate hyperproliferation of keratinocyts resulting in the typical psoriatic symptoms. Therefore, alefacept leads to clinical improvement of moderate to severe psoriasis by blunting these reactions.</p>
<p><a name="Drawbacks" id="Drawbacks"></a></p>
<h2><span class="editsection">[<a href="../../../a/l/e/Alefacept.html" title="Edit section: Drawbacks">edit</a>]</span> <span class="mw-headline">Drawbacks</span></h2>
<p>Due to safety issues (immunosuppression, risk of <a href="../../../i/n/f/Infection.html" title="Infection">infections</a>, <a href="../../../m/a/l/Malignant.html" title="Malignant">malignancies</a>, and <a href="../../../a/l/l/Allergy.html" title="Allergy">allergies</a>) the European Medicines Agency (<a href="../../../e/u/r/European_Medicines_Agency_e04e.html" title="European Medicines Agency">EMEA</a>) has so far rejected to approve alefacept.</p>
<p><a name="Indications" id="Indications"></a></p>
<h2><span class="editsection">[<a href="../../../a/l/e/Alefacept.html" title="Edit section: Indications">edit</a>]</span> <span class="mw-headline">Indications</span></h2>
<p>Alefacept is indicated for the management of patients with moderate to severe chronic plaque psoriasis in adult patients who are candidates for systemic therapy or <a href="../../../p/h/o/Phototherapy.html" title="Phototherapy">phototherapy</a>. The concomitant use of low-potency topical <a href="../../../c/o/r/Corticosteroid.html" title="Corticosteroid">corticosteroids</a> was permitted during the treatment phase with alefacept and does not seem to pose any additional risks.</p>
<p>The drug was approved based upon studies involving 1,869 patients altogether with plaques covering at least 10% of body surface. Either 7.5 mg IV or 15 mg IM once a week were applied. The long term results (reduction of at least 75% in pretreatment <a href="../../../p/s/o/Psoriasis.html#Severity" title="Psoriasis">PASI scores</a>) were 14% and 21%, respectively. Additional improvements ensuing after completion of the 12-week treatment phase or after completion of a second alefacept treatment were also seen. Often the <a href="../../../r/e/m/Remission.html" title="Remission">remissions</a> were maintained for 7 to 12 months after end of treatment.</p>
<p><a name="Contraindications_and_Precautions" id="Contraindications_and_Precautions"></a></p>
<h2><span class="editsection">[<a href="../../../a/l/e/Alefacept.html" title="Edit section: Contraindications and Precautions">edit</a>]</span> <span class="mw-headline">Contraindications and Precautions</span></h2>
<ul>
<li>Alefacept reduces <a href="../../../t/_/h/T_helper_cell.html" title="T helper cell">CD4<sup>+</sup> T cell</a> counts and may worsen the clinical course of <a href="../../../h/i/v/HIV_infection_77d3.html" title="HIV infection">HIV infections</a>. It is therefore contraindicated in patients with HIV infections.</li>
<li>Pretreatment CD4<sup>+</sup> and/or <a href="../../../c/y/t/Cytotoxic_T_cell_e808.html" title="Cytotoxic T cell">CD8<sup>+</sup> cell</a> counts below the accepted lower limit</li>
<li>History of systemic malignancy</li>
<li>Caution: Patients at high risk to develop a systemic malignancy</li>
<li>Known <a href="../../../h/y/p/Hypersensitivity.html" title="Hypersensitivity">hypersensitivity</a> to alefacept or to any other ingredient of the preparation</li>
<li>Caution: There is little experience in geriatric patients (65 years of age or older); so far no differences to the younger age group have been noted.</li>
</ul>
<p><a name="Pregnancy_and_Lactation" id="Pregnancy_and_Lactation"></a></p>
<h2><span class="editsection">[<a href="../../../a/l/e/Alefacept.html" title="Edit section: Pregnancy and Lactation">edit</a>]</span> <span class="mw-headline">Pregnancy and Lactation</span></h2>
<ul>
<li>Alefacept has been assigned to Pregnancy Category B in the US and to C in Australia.</li>
<li>Lactation&#160;: It is not known if the drug is excreted into human milk. Either the drug or <a href="../../../b/r/e/Breastfeeding.html" title="Breastfeeding">breastfeeding</a> should be terminated, taking into account the importance of treatment to the mother.</li>
</ul>
<p><a name="Pediatric_Patients" id="Pediatric_Patients"></a></p>
<h2><span class="editsection">[<a href="../../../a/l/e/Alefacept.html" title="Edit section: Pediatric Patients">edit</a>]</span> <span class="mw-headline">Pediatric Patients</span></h2>
<p>No clinical experience exists in patients under 18 years of age. The drug should therefore not be used in pediatric patients.</p>
<p><a name="Side_effects" id="Side_effects"></a></p>
<h2><span class="editsection">[<a href="../../../a/l/e/Alefacept.html" title="Edit section: Side effects">edit</a>]</span> <span class="mw-headline"><a href="../../../a/d/v/Adverse_drug_reaction.html" title="Adverse drug reaction">Side effects</a></span></h2>
<ul>
<li><a href="../../../l/y/m/Lymphopenia.html" title="Lymphopenia">Lymphopenia</a>&#160;: Most common in clinical trials was a significant and dose-related reduction of CD4+ and CD8+ counts in 10 to 59% of patients. However, only 0 to 2% of patients experienced reductions below the accepted lower limit. Consequences of lymphopenia may be infections and/or treatment related malignancies (see below).</li>
<li>Malignancies&#160;: In clinical studies among 1,869 patients 63 treatment-emerged malignancies in 43 patients were observed. Most of these were nonmelanoma and <a href="../../../m/e/l/Melanoma.html" title="Melanoma">melanoma</a> <a href="../../../s/k/i/Skin_cancer.html" title="Skin cancer">skin cancers</a>, other solid tumors, and <a href="../../../l/y/m/Lymphoma.html" title="Lymphoma">lymphomas</a>.</li>
<li>Infections&#160;: In clinical studies 0.9% of patients experienced significant infections compared to 0.2% in the placebo group. Among the infections were serious ones such as <a href="../../../s/e/p/Sepsis.html" title="Sepsis">sepsis</a>, <a href="../../../p/n/e/Pneumonia.html" title="Pneumonia">pneumonia</a>, <a href="../../../a/b/s/Abscess.html" title="Abscess">abscesses</a>, wound infections and <a href="../../../t/o/x/Toxic_shock_syndrome.html" title="Toxic shock syndrome">toxic shock syndrome</a>.</li>
<li>Sensitivity reactions: <a href="../../../u/r/t/Urticaria.html" title="Urticaria">Urticaria</a> and <a href="../../../a/n/g/Angioedema.html" title="Angioedema">angioedema</a> were observed. If an <a href="../../../a/n/a/Anaphylactic_reaction.html" title="Anaphylactic reaction">anaphylactic reaction</a> should occur symptomatic treatment should be initiated at once.</li>
<li>Forming of <a href="../../../a/n/t/Antibody.html" title="Antibody">antibodies</a> to alefacept&#160;: About 3% of patients developed low-titer antibodies with unknown importance for the clinical efficiency of the drug. Longterm immune effects have not been well explored.</li>
<li>Hepatic Toxicity&#160;: Postmarketing reports revealed asymtomatic increases in <a href="../../../t/r/a/Transaminases.html" title="Transaminases">transaminases</a> (<a href="../../../a/l/a/Alanine_transaminase.html" title="Alanine transaminase">ALT</a> and/or <a href="../../../a/s/p/Aspartate_transaminase.html" title="Aspartate transaminase">AST</a>), fatty liver degeneration, decompensation of preexisting <a href="../../../l/i/v/Liver_cirrhosis.html" title="Liver cirrhosis">liver cirrhosis</a>, and acute treatment-related <a href="../../../l/i/v/Liver_failure.html" title="Liver failure">liver failure</a>. It is not known if some or all of these manifestations are attributable to alefacept-therapy, but it is recommended to discontinue therapy as soon as any sign of liver toxicity develops.</li>
<li>Different Common Side Effects&#160;: side effects such as <a href="../../../p/h/a/Pharyngitis.html" title="Pharyngitis">pharyngitis</a>, <a href="../../../c/o/u/Cough.html" title="Cough">cough</a>, <a href="../../../d/i/z/Dizziness.html" title="Dizziness">dizziness</a>, <a href="../../../n/a/u/Nausea.html" title="Nausea">nausea</a>, <a href="../../../p/r/u/Pruritus.html" title="Pruritus">pruritus</a>, <a href="../../../m/y/a/Myalgia.html" title="Myalgia">myalgias</a>, <a href="../../../r/i/g/Rigor_%28medicine%29.html" title="Rigor (medicine)">chills</a>, and reactions at injection sites were observed quite frequently.</li>
</ul>
<p><a name="Interactions" id="Interactions"></a></p>
<h2><span class="editsection">[<a href="../../../a/l/e/Alefacept.html" title="Edit section: Interactions">edit</a>]</span> <span class="mw-headline">Interactions</span></h2>
<ul>
<li>Patients currently undergoing immunosuppressive therapy (phototherapy, or concomitant application of other immunosuppressant agents) should not receive alefacept in order to avoid the risks of excessive immunosuppression. Studies concerning the combination with <a href="../../../c/y/c/Cyclosporine.html" title="Cyclosporine">cyclosporine</a> or <a href="../../../m/e/t/Methotrexate.html" title="Methotrexate">methotrexate</a> are conducted, but no results have been published so far.</li>
<li>Live vaccines&#160;: The efficiency of concomitant application of live <a href="../../../v/a/c/Vaccine.html" title="Vaccine">vaccines</a> has not been fully examined yet. However, the effect of <a href="../../../t/e/t/Tetanus.html" title="Tetanus">tetanus</a> <a href="../../../t/o/x/Toxoid.html" title="Toxoid">toxoid</a> was well preserved in clinical trials.</li>
</ul>
<p><a name="Necessary_Laboratory_Examinations" id="Necessary_Laboratory_Examinations"></a></p>
<h2><span class="editsection">[<a href="../../../a/l/e/Alefacept.html" title="Edit section: Necessary Laboratory Examinations">edit</a>]</span> <span class="mw-headline">Necessary Laboratory Examinations</span></h2>
<ul>
<li>CD4<sup>+</sup> cell counts should be obtained before initiation of therapy and during the 12-week course of therapy in intervals of 2 weeks.</li>
<li>It may be desirable to monitor <a href="../../../l/i/v/Liver_function_tests.html" title="Liver function tests">liver function studies</a> (AST and ALT) in patients at high risk to develop liver toxicity (e.g., preexisting hepatitis, or high daily consumption of alcohol).</li>
</ul>
<p><a name="Dosage_Regimes" id="Dosage_Regimes"></a></p>
<h2><span class="editsection">[<a href="../../../a/l/e/Alefacept.html" title="Edit section: Dosage Regimes">edit</a>]</span> <span class="mw-headline">Dosage Regimes</span></h2>
<p>The standard dosage regime is the weekly application of either 7.5 mg IV or 15 mg IM for a course of 12 weeks. The benefits and risks of repeated courses have not been explored in sufficient detail. Therapy should be conducted under the supervision of a physician experienced in the use of immunosuppressant agents.</p>
<p><a name="Notes" id="Notes"></a></p>
<h2><span class="editsection">[<a href="../../../a/l/e/Alefacept.html" title="Edit section: Notes">edit</a>]</span> <span class="mw-headline">Notes</span></h2>
<div class="references-small">
<ol class="references">
<li id="_note-0"><b><a href="#_ref-0" title="">^</a></b> <cite style="font-style:normal">(2004) "<a href="http://www.australianprescriber.com/magazine/27/4/101/5/" class="external text" title="http://www.australianprescriber.com/magazine/27/4/101/5/" rel="nofollow"><b>New drugs</b></a>". <i>Australian Prescriber</i> <b>27</b> (101): 5. Retrieved on <a href="../../../2/0/0/2006.html" title="2006">2006</a>-<a href="../../../a/u/g/August_20.html" title="August 20">08-20</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.atitle=%27%27%27New+drugs%27%27%27&amp;rft.title=Australian+Prescriber&amp;rft.jtitle=Australian+Prescriber&amp;rft.date=2004&amp;rft.volume=27&amp;rft.issue=101&amp;rft.pages=5&amp;rft_id=http%3A%2F%2Fwww.australianprescriber.com%2Fmagazine%2F27%2F4%2F101%2F5%2F">&#160;</span></li>
</ol>
</div>
<p><a name="External_links" id="External_links"></a></p>
<h2><span class="editsection">[<a href="../../../a/l/e/Alefacept.html" title="Edit section: External links">edit</a>]</span> <span class="mw-headline">External links</span></h2>
<ul>
<li><cite style="font-style:normal">Koo J, Bagel J, Sweetser M, Ticho B. "Alefacept in combination with ultraviolet B phototherapy for the treatment of chronic plaque psoriasis: results from an open-label, multicenter study.". <i>J Drugs Dermatol</i> <b>5</b> (7): 623-8. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16865867" class="external" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16865867">PMID 16865867</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.atitle=Alefacept+in+combination+with+ultraviolet+B+phototherapy+for+the+treatment+of+chronic+plaque+psoriasis%3A+results+from+an+open-label%2C+multicenter+study.&amp;rft.title=J+Drugs+Dermatol&amp;rft.jtitle=J+Drugs+Dermatol&amp;rft.volume=5&amp;rft.issue=7&amp;rft.au=Koo+J%2C+Bagel+J%2C+Sweetser+M%2C+Ticho+B&amp;rft.pages=623-8">&#160;</span></li>
<li><cite style="font-style:normal">Krell J (2006). "Use of alefacept and etanercept in 3 patients whose psoriasis failed to respond to etanercept.". <i>J Am Acad Dermatol</i> <b>54</b> (6): 1099-101. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16713481" class="external" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16713481">PMID 16713481</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.atitle=Use+of+alefacept+and+etanercept+in+3+patients+whose+psoriasis+failed+to+respond+to+etanercept.&amp;rft.title=J+Am+Acad+Dermatol&amp;rft.jtitle=J+Am+Acad+Dermatol&amp;rft.date=2006&amp;rft.volume=54&amp;rft.issue=6&amp;rft.au=Krell+J&amp;rft.pages=1099-101">&#160;</span></li>
<li><cite style="font-style:normal">Parrish C, Sobera J, Robbins C, Cantrell W, Desmond R, Elewski B (2006). "Alefacept in the treatment of psoriatic nail disease: a proof of concept study.". <i>J Drugs Dermatol</i> <b>5</b> (4): 339-40. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16673801" class="external" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16673801">PMID 16673801</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.atitle=Alefacept+in+the+treatment+of+psoriatic+nail+disease%3A+a+proof+of+concept+study.&amp;rft.title=J+Drugs+Dermatol&amp;rft.jtitle=J+Drugs+Dermatol&amp;rft.date=2006&amp;rft.volume=5&amp;rft.issue=4&amp;rft.au=Parrish+C%2C+Sobera+J%2C+Robbins+C%2C+Cantrell+W%2C+Desmond+R%2C+Elewski+B&amp;rft.pages=339-40">&#160;</span></li>
<li>AHFS Database online</li>
</ul>
<div class="NavFrame" style="clear:both;">
<div class="NavHead" style="background:#ccccff;">
<div class="noprint plainlinksneverexpand" style="background-color:transparent; padding:0; font-weight:normal; font-size:xx-small; color:#000000; white-space:nowrap; position:absolute; width:auto; left:0.5em;"><a href="../../../i/m/m/Template%7EImmunosuppressants_9ba4.html" title="Template:Immunosuppressants"><span title="View this template">v</span></a>&#160;<span style="font-size:80%;">•</span>&#160;<span style="color: #002bb8;" title="Discussion about this template">d</span>&#160;<span style="font-size:80%;">•</span>&#160;<a href="http://en.wikipedia.org../../../i/m/m/Template%7EImmunosuppressants_9ba4.html" class="external text" title="http://en.wikipedia.org../../../i/m/m/Template%7EImmunosuppressants_9ba4.html" rel="nofollow"><span style="color: #002bb8;" title="You can edit this template. Please use the preview button before saving.">e</span></a></div>
<b><a href="../../../i/m/m/Immunosuppressive_drug.html" title="Immunosuppressive drug">Immunosuppressants</a> (<a href="../../../a/t/c/ATC_code_L04_d7fc.html" title="ATC code L04">L04</a>)</b></div>
<div class="NavContent" style="margin:0.5em; font-size:0.9em;">
<p><a href="../../../a/b/a/Abatacept.html" title="Abatacept">Abatacept</a>, Abetimus, <a href="../../../a/d/a/Adalimumab.html" title="Adalimumab">Adalimumab</a>, <a href="../../../a/f/e/Afelimomab.html" title="Afelimomab">Afelimomab</a>, <a href="../../../a/n/a/Anakinra.html" title="Anakinra">Anakinra</a>, <strong class="selflink">Alefacept</strong>, Antilymphocyte immunoglobulin (horse), Antithymocyte immunoglobulin (rabbit), <a href="../../../a/s/e/Aselizumab.html" title="Aselizumab">Aselizumab</a>, <a href="../../../a/t/l/Atlizumab.html" title="Atlizumab">Atlizumab</a>, <a href="../../../a/t/o/Atorolimumab.html" title="Atorolimumab">Atorolimumab</a>, <a href="../../../a/z/a/Azathioprine.html" title="Azathioprine">Azathioprine</a>, <a href="../../../b/a/s/Basiliximab.html" title="Basiliximab">Basiliximab</a>, <a href="../../../b/e/l/Belatacept.html" title="Belatacept">Belatacept</a>, <a href="../../../b/e/l/Belimumab.html" title="Belimumab">Belimumab</a>, <a href="../../../b/e/r/Bertilimumab.html" title="Bertilimumab">Bertilimumab</a>, <a href="../../../c/e/d/Cedelizumab.html" title="Cedelizumab">Cedelizumab</a>, <a href="../../../c/i/c/Ciclosporin.html" title="Ciclosporin">Ciclosporin</a>, <a href="../../../c/i/t/Citilimumab.html" title="Citilimumab">Citilimumab</a>, <a href="../../../c/l/e/Clenoliximab.html" title="Clenoliximab">Clenoliximab</a>, <a href="../../../d/a/c/Daclizumab.html" title="Daclizumab">Daclizumab</a>, Difirolimus, Dofosirolimus, <a href="../../../d/o/r/Dorlimomab_aritox.html" title="Dorlimomab aritox">Dorlimomab aritox</a>, <a href="../../../e/c/u/Eculizumab.html" title="Eculizumab">Eculizumab</a>, <a href="../../../e/f/a/Efalizumab.html" title="Efalizumab">Efalizumab</a>, <a href="../../../e/l/s/Elsilimomab.html" title="Elsilimomab">Elsilimomab</a>, <a href="../../../e/n/l/Enlimomab.html" title="Enlimomab">Enlimomab</a>, <a href="../../../e/n/l/Enlimomab_pegol.html" title="Enlimomab pegol">Enlimomab pegol</a>, <a href="../../../e/r/l/Erlizumab.html" title="Erlizumab">Erlizumab</a>, <a href="../../../e/t/a/Etanercept.html" title="Etanercept">Etanercept</a>, <a href="../../../e/v/e/Everolimus.html" title="Everolimus">Everolimus</a>, <a href="../../../f/a/r/Faralimomab.html" title="Faralimomab">Faralimomab</a>, <a href="../../../f/o/n/Fontolizumab.html" title="Fontolizumab">Fontolizumab</a>, <a href="../../../g/a/l/Galiximab.html" title="Galiximab">Galiximab</a>, <a href="../../../g/a/v/Gavilimomab.html" title="Gavilimomab">Gavilimomab</a>, Gifosirolimus, <a href="../../../g/o/l/Golimumab.html" title="Golimumab">Golimumab</a>, <a href="../../../g/o/m/Gomiliximab.html" title="Gomiliximab">Gomiliximab</a>, <a href="../../../g/u/s/Gusperimus.html" title="Gusperimus">Gusperimus</a>, <a href="../../../i/n/f/Infliximab.html" title="Infliximab">Infliximab</a>, <a href="../../../i/n/o/Inolimomab.html" title="Inolimomab">Inolimomab</a>, <a href="../../../i/p/i/Ipilimumab.html" title="Ipilimumab">Ipilimumab</a>, <a href="../../../k/e/l/Keliximab.html" title="Keliximab">Keliximab</a>, <a href="../../../l/e/f/Leflunomide.html" title="Leflunomide">Leflunomide</a>, <a href="../../../l/e/r/Lerdelimumab.html" title="Lerdelimumab">Lerdelimumab</a>, <a href="../../../l/u/m/Lumiliximab.html" title="Lumiliximab">Lumiliximab</a>, <a href="../../../m/a/s/Maslimomab.html" title="Maslimomab">Maslimomab</a>, <a href="../../../m/e/p/Mepolizumab.html" title="Mepolizumab">Mepolizumab</a>, <a href="../../../m/e/t/Metelimumab.html" title="Metelimumab">Metelimumab</a>, <a href="../../../m/e/t/Methotrexate.html" title="Methotrexate">Methotrexate</a>, Morolimumab, <a href="../../../m/u/r/Muromonab-CD3_9775.html" title="Muromonab-CD3">Muromonab-CD3</a>, <a href="../../../m/y/c/Mycophenolic_acid.html" title="Mycophenolic acid">Mycophenolic acid</a>, <a href="../../../n/a/t/Natalizumab.html" title="Natalizumab">Natalizumab</a>, <a href="../../../n/e/r/Nerelimomab.html" title="Nerelimomab">Nerelimomab</a>, <a href="../../../o/c/r/Ocrelizumab.html" title="Ocrelizumab">Ocrelizumab</a>, <a href="../../../o/d/u/Odulimomab.html" title="Odulimomab">Odulimomab</a>, <a href="../../../o/m/a/Omalizumab.html" title="Omalizumab">Omalizumab</a>, <a href="../../../p/a/s/Pascolizumab.html" title="Pascolizumab">Pascolizumab</a>, <a href="../../../p/e/x/Pexelizumab.html" title="Pexelizumab">Pexelizumab</a>, <a href="../../../p/i/m/Pimecrolimus.html" title="Pimecrolimus">Pimecrolimus</a>, <a href="../../../r/e/s/Reslizumab.html" title="Reslizumab">Reslizumab</a>, <a href="../../../r/o/v/Rovelizumab.html" title="Rovelizumab">Rovelizumab</a>, <a href="../../../r/u/p/Ruplizumab.html" title="Ruplizumab">Ruplizumab</a>, Safosirolimus, <a href="../../../s/i/p/Siplizumab.html" title="Siplizumab">Siplizumab</a>, <a href="../../../s/i/r/Sirolimus.html" title="Sirolimus">Sirolimus</a>, <a href="../../../t/a/c/Tacrolimus.html" title="Tacrolimus">Tacrolimus</a>, <a href="../../../t/a/l/Talizumab.html" title="Talizumab">Talizumab</a>, <a href="../../../t/e/l/Telimomab_aritox.html" title="Telimomab aritox">Telimomab aritox</a>, <a href="../../../t/e/n/Teneliximab.html" title="Teneliximab">Teneliximab</a>, <a href="../../../t/h/a/Thalidomide.html" title="Thalidomide">Thalidomide</a>, <a href="../../../t/i/c/Ticilimumab.html" title="Ticilimumab">Ticilimumab</a>, <a href="../../../t/i/l/Tilolizumab.html" title="Tilolizumab">Tilolizumab</a>, <a href="../../../t/o/c/Tocilizumab.html" title="Tocilizumab">Tocilizumab</a>, <a href="../../../t/o/r/Toralizumab.html" title="Toralizumab">Toralizumab</a>, Torolimus, <a href="../../../v/a/p/Vapaliximab.html" title="Vapaliximab">Vapaliximab</a>, <a href="../../../v/e/p/Vepalimomab.html" title="Vepalimomab">Vepalimomab</a>, <a href="../../../v/i/s/Visilizumab.html" title="Visilizumab">Visilizumab</a>, <a href="../../../z/a/n/Zanolimumab.html" title="Zanolimumab">Zanolimumab</a>, <a href="../../../z/i/r/Ziralimumab.html" title="Ziralimumab">Ziralimumab</a>, <a href="../../../z/o/l/Zolimomab_aritox.html" title="Zolimomab aritox">Zolimomab aritox</a></p>
</div>
</div>

<!-- 
Pre-expand include size: 49420 bytes
Post-expand include size: 22728 bytes
Template argument size: 9732 bytes
Maximum: 2048000 bytes
-->
<div class="printfooter">
Retrieved from "<a href="http://en.wikipedia.org../../../a/l/e/Alefacept.html">http://en.wikipedia.org../../../a/l/e/Alefacept.html</a>"</div>
	    <div id="catlinks"><p class='catlinks'><a href="../../../c/a/t/Special%7ECategories_101d.html" title="Special:Categories">Category</a>: <span dir='ltr'><a href="../../../i/m/m/Category%7EImmunosuppressive_agents_dd3c.html" title="Category:Immunosuppressive agents">Immunosuppressive agents</a></span></p></div>	    <!-- end content -->
	    <div class="visualClear"></div>
	  </div>
	</div>
      </div>
      <div id="column-one">
	<div id="p-cactions" class="portlet">
	  <h5>Views</h5>
	  <ul>
	    <li id="ca-nstab-main"
	       class="selected"	       ><a href="../../../a/l/e/Alefacept.html">Article</a></li><li id="ca-talk"
	       class="new"	       ><a href="../../../a/l/e/Talk%7EAlefacept_f158.html">Discussion</a></li><li id="ca-current"
	       	       ><a href="http://en.wikipedia.org/wiki/Alefacept">Current revision</a></li>	  </ul>
	</div>
	<div class="portlet" id="p-logo">
	  <a style="background-image: url(../../../images/wiki-en.png);"
	    href="../../../index.html"
	    title="Main Page"></a>
	</div>
	<script type="text/javascript"> if (window.isMSIE55) fixalpha(); </script>
		<div class='portlet' id='p-navigation'>
	  <h5>Navigation</h5>
	  <div class='pBody'>
	    <ul>
	    	      <li id="n-Main-page"><a href="../../../index.html">Main page</a></li>
	     	      <li id="n-Contents"><a href="../../../c/o/n/Wikipedia%7EContents_3181.html">Contents</a></li>
	     	      <li id="n-Featured-content"><a href="../../../f/e/a/Wikipedia%7EFeatured_content_24ba.html">Featured content</a></li>
	     	      <li id="n-currentevents"><a href="../../../c/u/r/Portal%7ECurrent_events_bb60.html">Current events</a></li>
	     	    </ul>
	  </div>
	</div>
		<div class='portlet' id='p-interaction'>
	  <h5>interaction</h5>
	  <div class='pBody'>
	    <ul>
	    	      <li id="n-About-Wikipedia"><a href="../../../a/b/o/Wikipedia%7EAbout_8d82.html">About Wikipedia</a></li>
	     	      <li id="n-portal"><a href="../../../c/o/m/Wikipedia%7ECommunity_Portal_6a3c.html">Community portal</a></li>
	     	      <li id="n-contact"><a href="../../../c/o/n/Wikipedia%7EContact_us_afd6.html">Contact us</a></li>
	     	      <li id="n-sitesupport"><a href="http://wikimediafoundation.org/wiki/Fundraising">Make a donation</a></li>
	     	      <li id="n-help"><a href="../../../c/o/n/Help%7EContents_22de.html">Help</a></li>
	     	    </ul>
	  </div>
	</div>
		<div id="p-search" class="portlet">
	  <h5><label for="searchInput">Search</label></h5>
	  <div id="searchBody" class="pBody">
	    <form action="javascript:goToStatic(3)" id="searchform"><div>
	      <input id="searchInput" name="search" type="text"
	        accesskey="f" value="" />
	      <input type='submit' name="go" class="searchButton" id="searchGoButton"
	        value="Go" />
	    </div></form>
	  </div>
	</div>
	      </div><!-- end of the left (by default at least) column -->
      <div class="visualClear"></div>
      <div id="footer">
    <div id="f-poweredbyico"><a href="http://www.mediawiki.org/"><img src="../../../skins/common/images/poweredby_mediawiki_88x31.png" alt="Powered by MediaWiki" /></a></div>	<div id="f-copyrightico"><a href="http://wikimediafoundation.org/"><img src="../../../images/wikimedia-button.png" border="0" alt="Wikimedia Foundation"/></a></div>	<ul id="f-list">
	  	  	  <li id="f-credits">This page was last modified 01:09, 25 February 2007 by Wikipedia user <a href="../../../s/e/l/User%7ESelket_adc6.html" title="User:Selket">Selket</a>. Based on work by Wikipedia user(s) DiamonDie, <a href="../../../f/i/r/User%7EFirsfron_bff1.html" title="User:Firsfron">Firsfron</a>, <a href="../../../b/l/u/User%7EBluebot_e595.html" title="User:Bluebot">Bluebot</a>, <a href="../../../f/v/a/User%7EFvasconcellos_4804.html" title="User:Fvasconcellos">Fvasconcellos</a>, <a href="../../../p/e/r/User%7EPeripitus_dfdd.html" title="User:Peripitus">Peripitus</a>, <a href="../../../b/e/n/User%7EBen.c.roberts_3e7a.html" title="User:Ben.c.roberts">Ben.c.roberts</a>, <a href="../../../s/k/a/User%7ESkapur_f77a.html" title="User:Skapur">Skapur</a> and <a href="../../../a/r/c/User%7EArcadian_5c4b.html" title="User:Arcadian">Arcadian</a> and Anonymous user(s) of Wikipedia.</li>	  <li id="f-copyright">All text is available under the terms of the <a class='internal' href="../../../t/e/x/Wikipedia%7EText_of_the_GNU_Free_Documentation_License_702a.html" title="Wikipedia:Text of the GNU Free Documentation License">GNU Free Documentation License</a>. (See <b><a class='internal' href="../../../c/o/p/Wikipedia%7ECopyrights_92c4.html" title="Wikipedia:Copyrights">Copyrights</a></b> for details.) <br /> Wikipedia&reg; is a registered trademark of the <a href="http://www.wikimediafoundation.org">Wikimedia Foundation, Inc</a>., a US-registered <a class='internal' href="../../../5/0/1/501%28c%29.html#501.28c.29.283.29" title="501(c)(3)">501(c)(3)</a> <a href="http://wikimediafoundation.org/wiki/Deductibility_of_donations">tax-deductible</a> <a class='internal' href="../../../n/o/n/Non-profit_organization.html" title="Non-profit organization">nonprofit</a> <a href="../../../c/h/a/Charitable_organization.html" title="Charitable organization">charity</a>.<br /></li>	  <li id="f-about"><a href="../../../a/b/o/Wikipedia%7EAbout_8d82.html" title="Wikipedia:About">About Wikipedia</a></li>	  <li id="f-disclaimer"><a href="../../../g/e/n/Wikipedia%7EGeneral_disclaimer_3e44.html" title="Wikipedia:General disclaimer">Disclaimers</a></li>	  	</ul>
      </div>
    </div>
  </body>
</html>
